Influences of the PPARα-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil
Fiche du document
- 20.500.11794/39669
- 1098-3600
- doi: 10.1097/00125817-200207000-00010
- 12172398
http://purl.org/coar/access_right/c_16ec
Mots-clés
Genetics Fibrates Lipid response Lipoproteins High-density lipoprotein cholesterol PPAR Fibrates Lipoprotéines de haute densité Obésité androïde Lipides plasmatiques Lipoprotéines plasmatiques Polymorphisme génétiqueSujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases Human males CholesterinCiter ce document
Martin Brochu et al., « Influences of the PPARα-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil », CorpusUL, l'archive ouverte de l'université Laval, ID : 10.1097/00125817-200207000-00010
Métriques
Partage / Export
Résumé
Purpose: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha). The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPAR alpha-L162V polymorphism. Methods: Sixty-three abdominally obese men were randomly assigned to a 6-month-intervention program with either receiving a placebo (N = 31) or gemfibrozil (N = 32). Results: In response to gemfibrozil therapy, L162-homozygotes exhibited a 5.5% increase in high-density lipoprotein 2 cholesterol (HDL(2)-C) levels compared with a 50.0% increase among carriers of the V162 allele (P = 0.03). Conclusion: These results suggest that the HDL(2)-C response to gemfibrozil is modulated by the PPAR alpha-L162V polymorphism.
